Ebola Vaccine Trial Launched in DR Congo

Prelims: Current events of national and international importance | Science & Technology | Health

Why in News?

Recently, the World Health Organization (WHO) launched the historic Tumaini clinical trial in Bunia (Ituri Province).

The trial seeks to evaluate whether the existing Ervebo vaccine, originally approved for the Zaire ebolavirus.
It can provide cross-protection against the Bundibugyo virus (Bundibugyo ebolavirus), which is driving the worst outbreak in DRC history.

Key Highlights

Ebola Virus Clinical Trial

Component	Operational Mechanism
Current Outbreak Context	The DRC is facing its largest and deadliest Bundibugyo outbreak on record (>9,700 cases, >4,600 deaths across eastern provinces). Africa CDC has declared it a Public Health Emergency of Continental Security (PHECS).
Ervebo Vaccine Profile	Developed as rVSV-ZEBOV (recombinant vesicular stomatitis virus carrying the surface glycoprotein of Zaire ebolavirus). Fully licensed for Zaire ebolavirus; the Tumaini Phase 2/3 trial tests whether it generates sufficient cross-reactive immunity against the Bundibugyo species.
Pipeline Vaccine Candidates	ChAdOx1 Bundibugyo - Monovalent adenoviral-vector candidate developed by the University of Oxford and Serum Institute of India (SII). mRNA-1469- Messenger RNA-based vaccine candidate developed by Moderna (funded by CEPI).
Vaccination Strategy	Uses a Ring Vaccination approach, inoculating direct contacts of confirmed cases, contacts of contacts, healthcare workers, pregnant women, and children aged 12 and above.

Ebola Virus Species

There are 6 known species belonging to the genus Ebolavirus (family Filoviridae).

Ebolavirus Species	Primary Outbreak Regions	Approved Dedicated Vaccines
*Zaire ebolavirus*	Central & West Africa	Ervebo (Merck), Zabdeno/Mvabea (J&J)
*Bundibugyo ebolavirus*	Uganda, DR Congo	No approved species-specific vaccine (Tumaini trial ongoing)
*Sudan ebolavirus*	Uganda, Sudan	No approved vaccine (Phase 2/3 candidates under evaluation)
*Taï Forest / Reston / Bombali*	Ivory Coast / Philippines / Sierra Leone	Reston/Bombali non-pathogenic in humans / No human vaccines

Strategic Significance

Existing licensed Ebola countermeasures target only Zaire ebolavirus.
Establishing cross-protection or validating species-specific candidates (Bundibugyo, Sudan) is critical for pandemic preparedness.
By including vulnerable demographics (pregnant women and children ≥12 years), the Tumaini trial sets a benchmark for ethical medical research during active humanitarian and epidemiological crises.

Reference

Aljazeera | Ebola vaccine clinical trial in DR Congo